FDA Asks for Characterization Data in ANDAs for Risperdal Generics

August 30, 2016

Applications for generics of Johnson & Johnson’s Risperdal should contain characterization data on the reference product and the copycat version, the FDA says.

In a draft guidance document released Monday, the FDA tells generics makers of the antipsychotic, which treats schizophrenia, to provide data on the polymer composition, weight distribution, molecular weight, and the polylactide-coglycolide architecture of the candidate and reference product.

The FDA notifies generics makers of the possibility that the agency may still request additional characterization data during the ANDA review.

View today's stories